Svb Leerink reissued their outperform rating on shares of Repligen (NASDAQ:RGEN) in a report published on Tuesday, Briefing.com Automated Import reports. Svb Leerink currently has a $100.00 target price on the biotechnology company’s stock. Svb Leerink also issued estimates for Repligen’s Q3 2019 earnings at $0.19 EPS, Q4 2019 earnings at $0.18 EPS, FY2019 earnings at $0.97 EPS, Q1 2020 earnings at $0.27 EPS, Q2 2020 earnings at $0.30 EPS, Q3 2020 earnings at $0.28 EPS, Q4 2020 earnings at $0.31 EPS, FY2020 earnings at $1.15 EPS and FY2021 earnings at $1.43 EPS.
Several other brokerages also recently issued reports on RGEN. First Analysis raised their price objective on shares of Repligen from $95.00 to $107.00 and gave the stock an outperform rating in a research note on Wednesday, August 28th. BidaskClub downgraded shares of Repligen from a strong-buy rating to a buy rating in a research note on Wednesday, September 11th. Zacks Investment Research downgraded shares of Repligen from a buy rating to a hold rating in a research note on Wednesday, August 7th. Craig Hallum raised their price objective on shares of Repligen from $80.00 to $108.00 and gave the stock a buy rating in a research note on Monday, August 5th. Finally, HC Wainwright reissued a buy rating and issued a $110.00 price objective on shares of Repligen in a research note on Monday, August 12th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Repligen has a consensus rating of Buy and a consensus price target of $100.88.
Shares of NASDAQ:RGEN traded down $0.49 during trading on Tuesday, reaching $78.77. The company’s stock had a trading volume of 10,373 shares, compared to its average volume of 902,472. The company has a current ratio of 2.25, a quick ratio of 1.88 and a debt-to-equity ratio of 0.02. Repligen has a 12 month low of $48.26 and a 12 month high of $99.25. The firm’s 50 day simple moving average is $81.80 and its two-hundred day simple moving average is $77.74. The stock has a market capitalization of $4.08 billion, a PE ratio of 107.92, a price-to-earnings-growth ratio of 4.65 and a beta of 1.14.
In other Repligen news, CEO Anthony Hunt sold 3,600 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $82.89, for a total value of $298,404.00. Following the completion of the sale, the chief executive officer now owns 223,013 shares of the company’s stock, valued at $18,485,547.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.70% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the company. Castleark Management LLC purchased a new position in shares of Repligen during the second quarter worth approximately $2,219,000. Marshall Wace LLP purchased a new position in shares of Repligen during the second quarter worth approximately $9,445,000. Laurion Capital Management LP purchased a new position in shares of Repligen during the second quarter worth approximately $1,864,000. Redhawk Wealth Advisors Inc. purchased a new position in shares of Repligen during the second quarter worth approximately $462,000. Finally, Navellier & Associates Inc purchased a new position in shares of Repligen during the second quarter worth approximately $647,000. 86.59% of the stock is currently owned by institutional investors and hedge funds.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: Mutual Funds
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.